Karyopharm Therapeutics Inc. Stock
With 12 Buy predictions and not the single Sell prediction the community is currently very high on Karyopharm Therapeutics Inc..
Based on the current price of 0.54 € the target price of 18 € shows a potential of 3225.94% for Karyopharm Therapeutics Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Karyopharm Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Unique positioning" there were negative voices in the community.
Pros and Cons of Karyopharm Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Karyopharm Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | 1.690% | -0.394% | -16.308% | -48.810% | -9.246% | -53.878% | -93.267% |
| Evolus Inc | -1.580% | 1.081% | -8.333% | -72.090% | -31.376% | -54.110% | -59.268% |
| Sangamo Therapeutics Inc. | -2.930% | 14.215% | 18.433% | -60.100% | 5.432% | -86.712% | -96.126% |
Comments
Karyopharm Therapeutics (NASDAQ:KPTI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) had its price target lowered by analysts at Royal Bank Of Canada from $30.00 to $19.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for KPTI provided by MarketBeat